1. Home
  2. CTOR vs IKNA Comparison

CTOR vs IKNA Comparison

Compare CTOR & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTOR
  • IKNA
  • Stock Information
  • Founded
  • CTOR 2021
  • IKNA 2016
  • Country
  • CTOR United States
  • IKNA United States
  • Employees
  • CTOR N/A
  • IKNA N/A
  • Industry
  • CTOR
  • IKNA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTOR
  • IKNA Health Care
  • Exchange
  • CTOR NYSE
  • IKNA Nasdaq
  • Market Cap
  • CTOR 89.9M
  • IKNA 81.6M
  • IPO Year
  • CTOR N/A
  • IKNA 2021
  • Fundamental
  • Price
  • CTOR $1.25
  • IKNA $1.49
  • Analyst Decision
  • CTOR Strong Buy
  • IKNA Buy
  • Analyst Count
  • CTOR 2
  • IKNA 2
  • Target Price
  • CTOR $4.50
  • IKNA $3.00
  • AVG Volume (30 Days)
  • CTOR 68.9K
  • IKNA 169.0K
  • Earning Date
  • CTOR 02-14-2025
  • IKNA 03-11-2025
  • Dividend Yield
  • CTOR N/A
  • IKNA N/A
  • EPS Growth
  • CTOR N/A
  • IKNA N/A
  • EPS
  • CTOR N/A
  • IKNA N/A
  • Revenue
  • CTOR N/A
  • IKNA $659,000.00
  • Revenue This Year
  • CTOR N/A
  • IKNA N/A
  • Revenue Next Year
  • CTOR N/A
  • IKNA N/A
  • P/E Ratio
  • CTOR N/A
  • IKNA N/A
  • Revenue Growth
  • CTOR N/A
  • IKNA N/A
  • 52 Week Low
  • CTOR $0.85
  • IKNA $1.22
  • 52 Week High
  • CTOR $49.00
  • IKNA $1.94
  • Technical
  • Relative Strength Index (RSI)
  • CTOR N/A
  • IKNA 48.35
  • Support Level
  • CTOR N/A
  • IKNA $1.40
  • Resistance Level
  • CTOR N/A
  • IKNA $1.60
  • Average True Range (ATR)
  • CTOR 0.00
  • IKNA 0.07
  • MACD
  • CTOR 0.00
  • IKNA 0.01
  • Stochastic Oscillator
  • CTOR 0.00
  • IKNA 47.62

About CTOR CITIUS ONCOLOGY INC

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Share on Social Networks: